Physician profile
Peter Sonkin
NPI 1003991167
$949,444.63
in general payments reported to CMS, 2019-2025
15 companies · $66.54 in 2025
The $66.54 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89K · 2020: $88K · 2021: $736K · 2022: $37K · 2023: $19.02 · 2024: $409 · 2025: $66.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $948,499.94 | 2019-2022 | |
| Harrow Eye, LLC | $316.36 | 2024 | |
| Genentech USA, INC. | $166.71 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $77.80 | 2019-2020 | |
| Astellas Pharma US INC | $75.22 | 2024-2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.44 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $43.90 | 2023-2024 | Syfovre |
| Alimera Sciences, INC. | $43.24 | 2021-2024 | Iluvien, Yutiq |
| Mallinckrodt Enterprises LLC | $42.90 | 2019 | |
| Carl Zeiss Meditec, INC. | $41.94 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $33.26 | 2020-2021 | |
| Abbvie INC. | $20.24 | 2024 | |
| Amgen INC. | $15.83 | 2025 | Pavblu |
| Regeneron Pharmaceuticals, INC. | $11.65 | 2019 | |
| Allergan, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,274,702.67 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Sonkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.